BridgeBio Net Income from 2010 to 2026
| BBOT Stock | 13.19 0.11 0.83% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -66.8 M | Current Value -63.5 M | Quarterly Volatility 29.5 M |
Check BridgeBio Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 6 M, Other Operating Expenses of 97.6 M or Total Operating Expenses of 97.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.87. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Oncology Valuation or Volatility modules.
BridgeBio | Net Income | Build AI portfolio with BridgeBio Stock |
Latest BridgeBio Oncology's Net Income Growth Pattern
Below is the plot of the Net Income of BridgeBio Oncology Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in BridgeBio Oncology financial statement analysis. It represents the amount of money remaining after all of BridgeBio Oncology Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BridgeBio Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Oncology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 7.6 M | 10 Years Trend |
|
Net Income |
| Timeline |
BridgeBio Net Income Regression Statistics
| Arithmetic Mean | (15,873,555) | |
| Coefficient Of Variation | (185.82) | |
| Mean Deviation | 24,215,577 | |
| Median | (43,357) | |
| Standard Deviation | 29,496,570 | |
| Sample Variance | 870T | |
| Range | 74.3M | |
| R-Value | (0.73) | |
| Mean Square Error | 431.2T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (4,274,098) | |
| Total Sum of Squares | 13920.8T |
BridgeBio Net Income History
Other Fundumenentals of BridgeBio Oncology
About BridgeBio Oncology Financial Statements
BridgeBio Oncology shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although BridgeBio Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in BridgeBio Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on BridgeBio Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.